Ignite Creation Date:
2024-05-05 @ 5:17 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00422721
Status:
COMPLETED
Last Update Posted:
2011-11-24
First Post:
2007-01-12
Brief Title:
Genetic Study of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy
Sponsor:
Nantes University Hospital
Organization:
Nantes University Hospital
Study Overview
Official Title:
Genetical Multi-center Prospective Study of Phenotyping and Genotyping of Patients Suffering From Congenital Amaurosis of Leber or From an Early Severe Retinal Dystrophy in the Aim of the Realisation of a Clinical Trial of Gene Therapy
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Retinal dystrophies are responsible for numerous cases of blindness and there are no therapeutic possibilities today Gene therapy is efficient in a dog model concerning dystrophy linked to a mutation of the rpe65 gene If such a therapy is to be considered for humans it is urgent to select at a national level patients suffering from dystrophy linked to a mutation of the rpe65 gene The systematic correlation of phenotypegenotype is an anatomical-functional approach but it also identifies patients who may be potentially included in a future gene therapy study Indeed identification of people with a mutation of rpe65 is still insufficient in France compared to other European countries because of a lack of systemic genotyping of retinal dystrophy
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ID RCB 2006-A00192-49 | None | None | None |